# Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

> **NCT04373317** · PHASE4 · RECRUITING · sponsor: **VA Office of Research and Development** · enrollment: 358 (estimated)

## Conditions studied

- Parkinson's Disease Psychosis

## Interventions

- **DRUG:** Pimavanserin
- **DRUG:** Quetiapine

## Key facts

- **NCT ID:** NCT04373317
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-24
- **Primary completion:** 2026-10-24
- **Final completion:** 2027-08-24
- **Target enrollment:** 358 (ESTIMATED)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04373317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04373317, "Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04373317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*